Brief: Moonlake Immunotherapeutics Announces The Full Dataset From Its 24-Week MIRA Clinical Trial

MoonLake Immunotherapeutics

15/10/2023 14:09

Oct 15 (Reuters) - MoonLake Immunotherapeutics  MLTX.O :
    * MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES THE FULL DATASET
FROM ITS
24-WEEK MIRA CLINICAL TRIAL, ESTABLISHING THE NANOBODY®
SONELOKIMAB AS A HIGHLY PROMISING AND DIFFERENTIATED THERAPEUTIC
SOLUTION FOR HIDRADENITIS SUPPURATIVA
    * MOONLAKE IMMUNOTHERAPEUTICS - SAFETY PROFILE OF
SONELOKIMAB WAS
CONSISTENT WITH PREVIOUSLY REPORTED STUDIES WITH NO NEW SAFETY
SIGNALS OBSERVED

Source text for Eikon:  ID:nGNE8f6Q0V 
Further company coverage:  MLTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))